e-learning
resources
Munich 2006
Tuesday 05.09.2006
Mechanisms of respiratory diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Vascular endothelial growth factor (VEGF) and airway inflammation in COPD. Correlation with pulmonary function
N. Rovina, A. Papapetropoulos, M. Michailidou, A. Kollintza, D. Simoes, C. Roussos, C. Gratziou (Athens, Greece)
Source:
Annual Congress 2006 - Mechanisms of respiratory diseases
Session:
Mechanisms of respiratory diseases
Session type:
Thematic Poster Session
Number:
3797
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Rovina, A. Papapetropoulos, M. Michailidou, A. Kollintza, D. Simoes, C. Roussos, C. Gratziou (Athens, Greece). Vascular endothelial growth factor (VEGF) and airway inflammation in COPD. Correlation with pulmonary function. Eur Respir J 2006; 28: Suppl. 50, 3797
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
A 62-year-old man with scanty mucoid sputum
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Vascular endothelial growth factor (VEGF) and bronchial wall remodelling in asthma
Source: Annual Congress 2004 - Genetics and molecular mechanisms of COPD and asthma
Year: 2004
Vascular endothelial growth factor (VEGF) levels in induced sputum and plasma in asymptomatic and COPD smokers. Correlation with airway and systemic inflammation
Source: Eur Respir J 2006; 28: Suppl. 50, 652s
Year: 2006
The clininical value of vascular endothelial growth factor (VEGF) in the development of lung sarcoidosis.
Source: International Congress 2018 – Sarcoidosis: from basic research to patient outcomes
Year: 2018
Bioavailability of vascular endothelial growth factor (VEGF)? A role in pulmonary fibrosis?
Source: Annual Congress 2012 - Fibrogenesis between epithelial injury and fibroblast proliferation
Year: 2012
Vascular endothelial growth factor (VEGF) , a specific marker of angiogenesis, is increased in asthmatic airways following allergen challenge
Source: Eur Respir J 2004; 24: Suppl. 48, 227s
Year: 2004
A role for vascular endothelial growth factor (VEGF) in fibrosis?
Source: Annual Congress 2009 - From emphysema to fibrosis: mechanisms of cellular remodelling in the diseased lung
Year: 2009
Increased binding activity of hypoxia inducible factor (HIF)-1α to vascular endothelial growth factor (VEGF) promoter region mediates enhanced vascular permeability in the lung of cystic fibrosis (CF) patients
Source: Eur Respir J 2003; 22: Suppl. 45, 173s
Year: 2003
Neutrophil vascular endothelial growth factor (VEGF) as a driving force for angiogenesis in bronchiectasis?
Source: International Congress 2016 – New findings in mucosal immunology
Year: 2016
Vascular endothelial growth factor levels in active pulmonary tuberculosis
Source: Eur Respir J 2002; 20: Suppl. 38, 610s
Year: 2002
Imbalance between vascular endothelial growth factor and endostatin in emphysema
Source: Eur Respir J 2003 Oct 01;22(4):609-612
Year: 2003
Vascular endothelial growth factor (VEGF) is a predictable marker for FEV1 progression in patients with Lymphangiolyomyomatosis (LAM).
Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases
Year: 2019
Placenta growth factor (PlGF) triggers small airway remodeling (SAR) in chronic obstructive pulmonary disease (COPD)
Source: International Congress 2017 – Insight into the pathogenesis of emphysema and pneumonia
Year: 2017
Role of corticosteroids in TNFα-induced expression of vascular endothelial growth factor (VEGF) in human airway smooth muscle cells
Source: Annual Congress 2003 - Cell signalling and cytokines in asthma
Year: 2003
Hypoxia inducible factor-1? in human emphysema lung tissue
Source: Eur Respir J 2011; 37: 775-783
Year: 2011
PTEN reduces vascular endothelial growth factor–mediated vascular permeability in asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 581s
Year: 2005
Vascular endothelial growth factor (VEGF) mRNA isoforms in an animal model of acute lung injury
Source: Annual Congress 2003 - Animal models of lung injury: useful or not?
Year: 2003
Circulating vascular endothelial growth factor and osteoporosis in patients with COPD
Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities
Year: 2010
VEGF reduces pulmonary hypertension and vascular remodeling in pulmonary fibrosis through reduced endothelial apoptosis
Source: Annual Congress 2009 - Pulmonary circulation I
Year: 2009
Increased vascular endothelial growth factor (VEGF) secretion from activated T cells in COPD
Source: Annual Congress 2007 - Cell-based tissue modulation: the good and the ugly?
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept